I'm thinking along those lines too GS.
No mention of funding with an estimated 2 Quarters of revenue remaining, and additional funding required for 2/3 trial. They had the opportunity to do a CR when the SP was twice the value. This implies they may have a funding arrangement / takeover in place?
That could be the reason for MT's departure i.e. strategic differences?
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst, page-1281
-
- There are more pages in this discussion • 144 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $82.65M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $125.5K | 754.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 162762 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 91996 | 3 |
View Market Depth
| Last trade - 16.10pm 12/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |